Skip to main content
    E

    Enanta Pharmaceuticals Inc (ENTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.69
    -1.98 (-18.56%)

    Market Cap: $310.77M

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Enanta Pharmaceuticals Inc (ENTA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Enanta Pharmaceuticals (ENTA) has a market cap of $310.77M and an enterprise value of $277.35M. Its share count is up 36.08% from a year earlier. It kept -96.89% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 10.75% below the market cap, as cash exceeds debt.

    Market Cap$310.77M
    Enterprise Value$277.35M
    Latest price (Nov 17, 2026)$8.69

    Key Dates

    The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 8, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndSeptember

    Share Statistics

    The share count rose 0.17% in the quarter ended Jun 30, 2026 and grew 17.19% a year over 2 years.

    Shares Outstanding29.09M
    Shares Change (YoY)+36.08%
    Shares Change (QoQ)+0.17%
    Share Count Growth (2Y CAGR)+17.19%

    Valuation Ratios

    Sales and book value multiples are 3.9x and 2.5x. Its year-end P/S ranged from 1.8x to 16.3x from 2016 to 2025.

    P/S Ratio3.9x
    Forward P/S4.9x
    P/B Ratio2.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 27.94% over 52 weeks and trades 26.23% below its 50-day average.

    Beta (1Y)1.10
    52-Week Change-27.94%
    1-Month Change-23.84%
    3-Month Change-35.68%
    6-Month Change-36.85%
    5-Year Change-87.52%
    10-Year Change-54.46%
    Total Return (1Y)-27.94%
    Total Return (3Y CAGR)-1.63%
    Total Return (5Y CAGR)-37.72%
    Return vs SPY (1Y)-41.25%
    Max Drawdown (1Y)-48.43%
    Max Drawdown (3Y)-75.60%
    Sharpe Ratio (1Y)-0.67
    Correlation with SPY (1Y)0.29
    50-Day Average$11.78
    200-Day Average$13.06
    52-Week Range$10.05 to $17.15
    RSI (14 Days)29.9
    Average Volume (20 Days)293.20K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.76x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.76x
    Quick Ratio3.76x
    Debt / Equity0.00x
    Interest Coverage-4.54x

    Returns and Efficiency

    Return on equity is -62.56% over the last 12 months, against a 5-year average of -67.21%.

    Return on Equity (ROE)-62.56%
    Return on Assets (ROA)-21.30%
    Return on Capital Employed (ROCE)-23.33%
    ROE (5Y Average)-67.21%
    ROA (5Y Average)-27.87%
    ROIC (5Y Average)-68.81%
    Asset Turnover0.22x
    Receivables Turnover9.10x

    Scores

    ENTA has an Altman Z-Score of -1.17, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-1.17
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $65.26M over the last 12 months is up 0.70% from the 12 months before.

    Revenue$65.26M
    Revenue Growth (YoY)+0.70%
    Gross Profit$65.26M
    Operating Income-$58.73M
    Pretax Income-$63.13M
    Net Income-$63.23M
    EBITDA-$51.38M
    EBIT-$56.62M
    Reported EPS (TTM)-$2.35

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 34.05% of the $296.87M in total assets.

    Cash and Equivalents$33.42M
    Total Debt$0
    Net Cash$33.42M
    Net Cash Per Share$1.15
    Working Capital$149.45M
    Shareholder Equity$101.07M
    Book Value Per Share$3.47
    Total Assets$296.87M
    Total Liabilities$195.80M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.62M of capital spending, operating cash flow left -$36.94M of free cash flow.

    Operating Cash Flow-$35.32M
    Capital Expenditures$1.62M
    Free Cash Flow-$36.94M
    FCF Per Share-$1.27
    Depreciation and Amortization$6.20M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -89.99%.

    Gross Margin100.00%
    Operating Margin-89.99%
    Pretax Margin-96.74%
    Net Margin-96.89%
    EBITDA Margin-78.74%
    EBIT Margin-86.77%
    FCF Margin-56.60%

    Growth

    Revenue fell 8.82% a year over 3 years.

    Revenue Growth (3Y CAGR)-8.82%
    Revenue Growth (5Y CAGR)-11.81%
    Book Value Per Share Growth (2Y CAGR)-45.77%
    Tangible Book Per Share Growth (2Y CAGR)-45.77%

    Revenue and profit by year

    Dividends and Yields

    ENTA does not pay a dividend. Its free cash flow yield is -14.61%.

    FCF Yield-14.61%
    Buyback Yield-27.67%
    Shareholder Yield-27.67%

    Peer Position

    Against 7 similar companies, ENTA has the 6th highest P/S.

    P/S Ratio3.9x vs 7.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)+0.70% vs -68.74% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ENTA

    What is ENTA's market cap?

    Enanta Pharmaceuticals has a market cap of $310.77M. Its enterprise value, which adds debt and subtracts cash, is $277.35M.

    How many shares of ENTA are outstanding?

    Enanta Pharmaceuticals has 29.09M shares outstanding. The count is up 36.08% from a year earlier.

    Does ENTA pay a dividend?

    No. Enanta Pharmaceuticals does not pay a dividend.

    How much debt does ENTA have?

    Enanta Pharmaceuticals has $0 of total debt and $33.42M of cash and equivalents, a net cash position of $33.42M.